Ipamorelin vs Tesamorelin: Two Probes of the Same Axis, at Two Different Levels
Most comparisons of these two compounds are written as rankings — which one releases more growth hormone, which one is cleaner, which one a laboratory should choose. That framing is wrong, and it is wrong in a way that costs experimental time. Ipamorelin and tesamorelin do not compete for the same position in an experimental design. They interrogate two different tiers of the somatotropic axis, and the published record contains a result showing that one of them stops working entirely when the tier above it is disconnected.
That result is the most useful thing in this literature for anyone planning a study, and it is almost never mentioned. It is where this comparison starts.
What each molecule binds
Ipamorelin is a pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, developed from a chemistry program that deleted the central Ala-Trp dipeptide of GHRP-1. It acts as an agonist at the growth hormone secretagogue receptor — the ghrelin receptor, GHS-R1a. Raun and colleagues established the pharmacology in 1998 and confirmed the receptor assignment using GHRP and GHRH antagonists, showing that ipamorelin releases GH through a GHRP-like receptor rather than the GHRH receptor.
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone, a 44-residue peptide corresponding to GHRH(1-44), and it acts at the GHRH receptor on the pituitary somatotroph. Dhillon’s 2011 reviews describe it as stimulating synthesis and release of endogenous growth hormone through that receptor.
So one compound works through the ghrelin arm and the other through the GHRH arm. Both converge on pituitary GH output. That much is uncontroversial, and it is where most write-ups stop.
The result that changes how you design the experiment
Popovic and colleagues published a study in 1995 that separates the two arms cleanly. Healthy controls and patients with hypothalamo-pituitary disconnection each received GHRH alone, GHRP-6 alone, and both together, with GH quantified as area under the curve over 120 minutes.
In controls, GHRH produced 483.7 ± 99.2, GHRP-6 produced 1434.8 ± 393.0, and the combination produced 3771.5 ± 399.6 — significantly greater than the arithmetic sum of the two given separately. That is a genuine supra-additive interaction, roughly double what simple addition predicts.
In the disconnection group the picture inverts. The GHRH response was essentially preserved at 423.4 ± 62.8, statistically indistinguishable from controls. The GHRP-6 response collapsed to 97.3 ± 7.9. And the combination fell to 745.3 ± 67.6, a value the authors report as not significantly different from the arithmetic addition of the two compounds given alone. The synergy did not shrink. It disappeared.
Rico and colleagues reached a compatible conclusion in lambs three years later by a different route. In cultured lamb adenohypophysial cells — pituitary tissue with no hypothalamus attached — GHRH plus GHRP-6 was not synergistic, and the combination was not significantly different from GHRH alone. In the intact animal, the same combination at low doses produced a higher GH peak and a higher area under the curve than GHRH by itself.
The implication for study design is direct and unforgiving. A secretagogue acting through GHS-R1a depends substantially on hypothalamic input for its effect. Move that compound into an isolated pituitary preparation and you have removed the machinery its principal action runs on. A GHRH-receptor agonist, by contrast, keeps working in that preparation because its receptor is on the somatotroph itself.
Choose the wrong model system and you will not measure a smaller effect. You will measure nothing, and you will not be able to tell that apart from the compound having failed.
Selectivity: what the 1998 data actually show
Ipamorelin’s reputation rests on selectivity, and in this case the reputation is supported by the primary text rather than by repetition. Raun’s group tested specificity in conscious swine and reported that none of the secretagogues examined affected plasma FSH, LH, prolactin or TSH. The divergence appeared in the stress axis: both GHRP-6 and GHRP-2 raised plasma ACTH and cortisol, while ipamorelin did not release either at levels significantly different from those following GHRH stimulation — and that held at exposures more than 200-fold above its ED50 for GH release.
That 200-fold margin is the specific, checkable number in this literature, and it is worth quoting instead of the vague “selective” that usually stands in for it. In the same swine work ipamorelin showed an ED50 of 2.3 ± 0.03 nmol/kg with a maximal response of 65 ± 0.2 ng GH/mL plasma, against 3.9 ± 1.4 nmol/kg and 74 ± 7 ng/mL for GHRP-6.
Note what those figures are: absolute concentrations from a defined swine protocol. Fold-over-baseline multipliers circulate widely in secondary write-ups of this compound and are not what the source reports.
The two evidence bases are not comparable in kind
Tesamorelin carries pooled data from two multicenter phase 3 trials in which 806 participants were randomized 2:1. At 26 weeks, visceral adipose tissue fell by 24 ± 41 cm² against a 2 ± 35 cm² increase on placebo, a treatment effect of −15.4%, while abdominal subcutaneous adipose tissue did not change significantly. IGF-I rose by 108 ± 112 ng/mL against −7 ± 64. Participants continuing through 52 weeks held a 17.5 ± 23.3% reduction.
Two details in that record matter more than the headline. First, the 26-week and 52-week figures are different measurements and should not be merged into a single range. Second, Dhillon’s reviews note that discontinuation during the extension phase led to reaccumulation of visceral adipose tissue — the effect is maintained by continued exposure, not banked.
Ipamorelin’s record is preclinical and narrower, and its most-cited animal finding is more equivocal than its citations suggest. Svensson and colleagues gave adult female Sprague-Dawley rats ipamorelin at 0.5 mg/kg per day by osmotic minipump for 12 weeks. Bone mineral content rose on DXA. But total bone mineral content corrected for the accompanying increase in body weight was unaffected, cortical volumetric bone mineral density was unchanged, and the authors attribute the cortical gain to increased cross-sectional bone area. The bones got bigger. They did not get denser. A summary that reports only “increased bone mineral content” has kept the headline and dropped the finding.
Outside bone, Venkova and colleagues examined ipamorelin in a rodent model of postoperative ileus, where a single intravenous dose shortened time to first bowel movement without altering cumulative fecal output, food intake or body weight gain over 48 hours, while repeated dosing at 0.1 or 1 mg/kg increased all three. Single-exposure and repeated-exposure designs gave different answers in the same model — another reason to specify the protocol before citing the result. This paper is frequently attributed to a different first author and an earlier year; the primary record lists Venkova, Mann, Nelson and Greenwood-Van Meerveld, 2009.
Sourcing these compounds for US laboratories
Procurement is where a US research group’s constraints diverge from the literature’s. Two points are worth stating plainly.
Tesamorelin is not in the Maple Research Labs catalog. A comparison article that quietly implies otherwise is doing its readers no favors. What is stocked, and what the GHS-R1a half of this comparison actually requires, is Ipamorelin 5mg with a batch certificate of analysis, held at 5 mg per vial — the figure that appears on the product page and on the certificate for the corresponding lot. Fill size is not a detail. A study computing exposure from a stated vial content is only as sound as the agreement between that number and the certificate, and where those two disagree the experiment inherits the error silently.
The second point is jurisdictional. Compounds sourced domestically and shipped same-day from Santa Barbara do not sit in a customs queue at ambient temperature for an indeterminate period, and the shipment does not depend on a broker’s classification decision. For lyophilized peptides the practical exposure is time and temperature in transit, and a domestic leg is materially shorter than a cross-border one. Maple Research Labs operates as a Wyoming entity shipping within the United States only.
What a certificate establishes, and what it does not
Certificates issued for this catalog report identity of sample, HPLC-UV purity and content, appearance, and a digital verification block. That scope is worth knowing precisely, because it bounds what can be claimed from it. An HPLC-UV chromatogram resolves species by retention and quantifies by absorbance. It does not confirm molecular mass, does not speciate counterion content, and does not measure water. For a five-residue peptide such as ipamorelin the risk profile is comparatively benign — two coupling steps, limited opportunity for deletion sequences — but “comparatively benign” is a statement about probability, not a substitute for orthogonal confirmation where a study’s conclusions turn on absolute content.
Laboratories that need mass confirmation or net peptide content should plan for it as separate analytical work rather than assume a purity certificate covers it.
Research use statement
All compounds referenced here are supplied for research use only. They are not for human use, not for veterinary use, and not for any diagnostic application. Every experimental subject described in the literature summarized above is an animal model, a cultured cell preparation, or a participant in a published clinical trial conducted under its own oversight. Nothing in this article is guidance for administration to any person.
References
Citation metadata below was retrieved and verified through PubMed.
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–61. PMID 9849822. DOI: https://doi.org/10.1530/eje.0.1390552
- Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked GHRP-6-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection. J Clin Endocrinol Metab. 1995;80(3):942–7. PMID 7883854. DOI: https://doi.org/10.1210/jcem.80.3.7883854
- Rico M, Rueda V, Lorenzo MT, Núñez A, De la Cruz LF. Effect of growth hormone-releasing peptide 1-6 on GH secretion stimulated by GHRH and pyridostigmine in lambs. J Physiol Biochem. 1998;54(2):67–76. PMID 9858126. No DOI assigned.
- Falutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010;95(9):4291–304. PMID 20554713. DOI: https://doi.org/10.1210/jc.2010-0490
- Dhillon S. Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. Drugs. 2011;71(8):1071–91. PMID 21668043. DOI: https://doi.org/10.2165/11202240-000000000-00000
- Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569–77. PMID 10828840. DOI: https://doi.org/10.1677/joe.0.1650569
- Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus. J Pharmacol Exp Ther. 2009;329(3):1110–6. PMID 19289567. DOI: https://doi.org/10.1124/jpet.108.149211
Research use only. Not for human use.